Jin Rong Jie·2026-03-18 01:53Core Viewpoint - The company has provided insights into its business performance and future plans during a recent investor conference, highlighting stable caffeine demand, growth in biopharmaceutical sales, and ongoing clinical developments in its product pipeline. Group 1: Caffeine Business - Global caffeine demand is expected to remain stable, with a decrease in caffeine prices in 2025, yet the company managed to maintain high revenue through increased sales [1][4] - Caffeine prices have stabilized since 2026, and the company will continue to monitor price trends [4] Group 2: Biopharmaceutical Business - 2025 marks the first full sales year for the products Enshuxing and Enyitan, with significant revenue growth anticipated [11] - The company expects that gross margin fluctuations in 2025 will not be indicative of future performance, as sales enter a normal phase [12] - The company is optimistic about the development of its biopharmaceutical business, supported by an expanding sales team and increased marketing efforts in 2026 [11] Group 3: Research and Development - The company plans to invest 1.036 billion yuan in R&D in 2025, with substantial investment continuing into 2026 [2][7] - Key products, including SYS6010, SYS6043, and SYS6002, are scheduled for data readouts at major academic conferences in the first half of 2026 [2][5] Group 4: Clinical Pipeline Updates - SYS6010 has entered Phase 3 clinical trials with multiple indications under accelerated development, including EGFR wild-type lung cancer [3][9] - SYS6002 is currently in Phase 3 clinical trials for cervical cancer, while SYS6043 and SYS6040 are in Phase 1 trials exploring multiple indications [3][9] - SYS6090 is focusing on late-stage solid tumors, with ongoing domestic trials and plans for international Phase 1 trials [10] Group 5: Market Position and Future Plans - The company submitted its main board listing application to the Hong Kong Stock Exchange in December 2025, and the process is ongoing [8] - Collaboration with AstraZeneca involves innovative peptide molecules currently in preclinical research, aimed at providing long-term treatment solutions for obesity and related issues [8]